Eli Lilly and Company (LLY) is a Healthcare company in the Drug Manufacturers - General industry with a 84% Strong Buy Score. Key strengths include Revenue Growth (42.6%), Gross Margin (83.0%), Net Margin (31.7%). Areas to watch: Debt/Equity (1.65). Our AI evaluates 8 fundamental categories including revenue growth, margin quality, balance sheet strength, cash flow generation, return on capital, and valuation metrics.
See how our AI analyzes LLY fundamentals to generate buy/sell signals and Strong Buy Scores.
Based on our AI-powered fundamental analysis, LLY has a Strong Buy Score of 84%, earning a "Strong Buy" rating. This score synthesizes 8 key financial metrics to provide an objective investment signal.
Eli Lilly and Company demonstrates robust fundamentals across multiple categories. Key strengths include Revenue Growth (42.6%) and Gross Margin (83.0%). The stock shows characteristics typically associated with outperformers.
Our AI analyzes Eli Lilly and Company's financial statements to generate buy/sell signals based on quantitative metrics, not market sentiment or news headlines. Here's what drives the 84% score:
Generate the full PDF report for complete category-by-category scoring and AI-powered investment recommendations.
Technical traders can view real-time demand and supply zones for LLY on our Demand Zones page. These zones identify key price levels where institutional buying or selling has historically occurred.
With LLY currently trading at $1028.83, our system monitors proximity to these critical levels and can alert you when the stock approaches support or resistance zones.
Subscribe to demand zone alerts to receive real-time notifications when LLY reaches key technical levels.
Eli Lilly and Company operates in the Healthcare sector, specifically in Drug Manufacturers - General. Understanding earnings trends is crucial for forecasting LLY's trajectory.
Current revenue growth of 42.6% significantly outpaces the average company. This strong growth trajectory supports a higher valuation multiple.
Visit our Earnings Calendar to track upcoming LLY earnings dates and historical beat/miss patterns. Sign up for earnings alerts to get notified before announcements.
Our AI projects LLY's trajectory based on current fundamentals and historical patterns. With a 84% Strong Buy Score, here's what the data suggests:
Bullish Outlook: Eli Lilly and Company shows strong fundamental momentum. Revenue growth of 42.6% suggests continued expansion. Net margins of 31.7% indicate pricing power and operational efficiency. Stocks with similar profiles have historically outperformed over 12-month periods.
For a complete 12-month price forecast with specific bull/bear scenarios, generate the full PDF report.
Understanding valuation is critical for determining if LLY is fairly priced. Here's the current snapshot:
Our AI weighs these metrics against growth rates and margin quality to determine if LLY offers compelling risk-adjusted returns at current prices.
Here's why investors are bullish on Eli Lilly and Company:
With a 84% Strong Buy Score, the bull case is well-supported by current fundamentals. The stock exhibits characteristics of quality compounders that tend to outperform long-term.
Every investment carries risk. Here are potential concerns for LLY investors:
The full PDF report includes a detailed bear case analysis with specific risk ratings for each category.
LLY Summary: Eli Lilly and Company earns a 84% Strong Buy Score based on AI analysis of fundamental data. Trading at $1028.83 with a $970.55B market cap, the stock shows strong fundamentals supporting a bullish 12-month outlook.
Bull Case: Revenue Growth (42.6%), Gross Margin (83.0%)
Watch: Debt/Equity (1.65)
For the complete analysis with specific price considerations, growth projections, and AI-powered buy/hold/sell recommendations, generate your free LLY PDF report.